P
ProHub
English 简体中文 繁體中文
Medium Merger & Acquisition

Sternofi

#Healthcare

Practice this intermediate merger & acquisition case interview question from LEK in the Healthcare sector. Includes detailed problem prompt, clarifying questions, structured framework, and expert recommendation. Part of ProHub's 835+ consulting case library.

ProHub Comment

This is a quantitative M&A case requiring candidates to build a market sizing model and conduct a financial break-even analysis. The case tests algebra skills and structured thinking, with the key challenge being organizing complex market share relationships into a coherent analytical framework. The ambiguous conclusion allows for either recommendation if logically supported, emphasizing that real-world business decisions often involve trade-offs rather than clear-cut answers.

Estimated Time 26 minutes
Difficulty Medium
Source NYU
22 / 100
Hamilton & Hamilton (H&H), a multinational pharmaceutical company, is considering acquiring Sternofi, a biotechnology company with a promising drug candidate in phase 2 clinical trials called Deanraghutumab. Should H&H go through with this acquisition?

Clarifying Information

  1. The drug candidate treats pancreatic cancer.
  2. Sternofi has several other drugs in its pipeline, but they are in earlier stages of development and it is too hard to predict how successful they will be at this point.
  3. Clinical trial data suggests Deanraghutumab may be more efficacious than the current standard of care, though, like many cancer drugs, it cannot treat 100% of cases.
  4. Focus only on the US market.
  5. H&H has few oncology products and is looking to expand into that therapeutic area.
Mock Interview
Interviewer

Hamilton & Hamilton (H&H), a multinational pharmaceutical company, is considering acquiring Sternofi, a biotechnology company with a promising drug candidate in phase 2 clinical trials called Deanraghutumab. Should H&H go through with this acquisition?

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

H&H must evaluate acquiring Sternofi for $2.3B based on projected revenues of a pancreatic cancer drug. The analysis requires calculating market share and pricing across competitors, then determining if the acquisition achieves H&H’s 8-year break-even target ($2.2B in cumulative net income versus $2.3B price).

Key Insights:

  1. Market sizing requires careful interpretation of relative market share relationships (Competitor A has 50% greater share than B; C has two-thirds less than A; Sternofi captures twice B’s share)
  2. Sternofi achieves market leadership by patient volume (30%) but highest revenue share (~50%) despite lower per-patient pricing, indicating pricing power is secondary to volume
  3. Break-even timeline is marginally tight (8.17 years vs. 8-year target), making synergies and risk mitigation critical decision factors
  4. Key risks include FDA approval uncertainty, patent protection duration, insurance reimbursement challenges, and competitive response—all affecting the $2.3B valuation assumption